Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immuno-embolization with GM-CSF for Uveal Melanoma Liver Metastases
NCT00661622Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Oct 2004
- Primary completion
- Dec 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sargramostim in Uveal melanoma (UM) (2 arms), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Overall Response Rate. Started Oct 2004; status: completed.
02
Drugs
sargramostim
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT00661622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00661622.